Instil Bio, Inc. Stock Price, News & Analysis

Instil Bio (NASDAQ: TIL) has appointed Dr. John Maraganore to the Board of Directors of its subsidiary Axion Bio, which is developing AXN-2510, a PD-L1xVEGF bispecific antibody targeting solid tumors with a focus on first-line non-small cell lung cancer (NSCLC). Dr. Maraganore, the founding CEO of Alnylam Pharmaceuticals, brings over 30 years of biotechnology experience and was instrumental in developing RNA interference (RNAi) into a validated therapeutic approach. The appointment comes as ImmuneOnco's Phase 2 trial of AXN-2510 combined with chemotherapy for first-line NSCLC approaches completion of enrollment this summer. The company believes AXN-2510 has shown promising early safety and efficacy data and could potentially become a best-in-class treatment for solid tumors.

Instil Bio (Nasdaq: TIL) has appointed Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman, a Hematologist-Oncologist with over 20 years of leadership experience in biopharma drug development, will focus on advancing AXN-2510, a PD-L1xVEGF bispecific therapy for solid tumors. His impressive track record includes 15 drug approvals across multiple therapeutic areas and executive roles at major pharmaceutical companies including Genentech, AstraZeneca, GSK, and Merck. Dr. Freedman holds M.D. and Ph.D. degrees from Tufts University and completed training at UCSF and Harvard. He maintains an active clinical practice at the UCSF VA Medical Center and has pioneered inclusive trials for underserved patients.

Instil Bio (Nasdaq: TIL), a clinical-stage biopharmaceutical company developing novel therapies, announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Bronson Crouch will deliver a presentation on Thursday, June 5, 2025, at 4:20 PM ET. Interested parties can access a live webcast of the presentation through the provided weblink. This conference participation represents an opportunity for Instil Bio to showcase its pipeline and developments to the investment community.

Instil Bio (Nasdaq: TIL) and ImmuneOnco Biopharmaceuticals (HKEX: 1541.HK) announced they will co-host an investor and analyst breakfast event in Chicago on May 31, 2025. The event, scheduled from 8:00 to 9:30 am CT near McCormick Convention Center, will feature company management and a key opinion leader in immuno-oncology. They will discuss the PD-(L)1xVEGF bispecific antibody landscape and provide clinical trial updates. Interested investors and analysts can register by emailing investorrelations@instilbio.com.

Instil Bio (NASDAQ: TIL) and ImmuneOnco provided updates on their PD-L1xVEGF bispecific antibody IMM2510/AXN-2510 ('2510) clinical trials. The Phase 2 trial of '2510 combined with chemotherapy for first-line NSCLC in China is expected to complete enrollment of ~60 patients in Q3 2025, with initial results anticipated in 2H 2025. In relapsed/refractory NSCLC, '2510 monotherapy showed a 23% objective response rate (n=13). Instil Bio plans to initiate a Phase 1b/2 monotherapy dose optimization trial in the US by end of 2025, replacing the previously planned first-line NSCLC combination trial. A Phase 3 trial in China for first-line NSCLC is anticipated to start in mid-2026, subject to regulatory discussions.

Instil Bio (NASDAQ: TIL) reported its Q1 2025 financial results and provided corporate updates. The company's key clinical trial of AXN-2510/IMM2510 in combination with chemotherapy for first-line NSCLC patients is progressing in China, with initial data expected in H2 2025. A U.S. clinical study is planned to begin by end of 2025, pending regulatory approvals. Financial highlights show $111.8 million in total cash and investments as of March 31, 2025, expected to fund operations beyond 2026. Q1 2025 saw reduced operating expenses with R&D at $5.4 million (vs $7.3M in Q1 2024) and G&A at $9.1 million (vs $12.4M in Q1 2024). However, restructuring charges increased to $16.1 million (vs $4.3M in Q1 2024). The company reported a basic and diluted net loss per share of $4.32, compared to $3.74 in Q1 2024.

Instil Bio (TIL) has reported its Q4 and full year 2024 financial results. The company ended 2024 with $115.1 million in total cash and equivalents, down from $175.0 million in 2023. Their cash runway is expected to extend beyond 2026.

Key clinical developments include anticipated data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China during 1H 2025, with additional safety data expected from approximately 100 patients across multiple solid tumors. ImmuneOnco plans to begin enrolling first-line NSCLC patients in Q2 2025 for a combination therapy trial with chemotherapy, with initial data expected in 2H 2025.

Financial highlights show reduced losses, with full-year 2024 net loss per share at $11.39, improved from $24.00 in 2023. R&D expenses decreased to $11.8 million in 2024 from $39.6 million in 2023, while G&A expenses slightly decreased to $44.2 million from $47.6 million.

Instil Bio (NASDAQ: TIL) announced significant progress in the clinical development of IMM2510/SYN-2510, a PD-L1xVEGF bispecific antibody, in China through its collaborator ImmuneOnco. The first patient has been dosed in a Phase 1b/2 clinical trial combining IMM2510/SYN-2510 with chemotherapy for advanced non-small cell lung cancer (NSCLC) patients.

ImmuneOnco plans to present initial clinical data from the trial, including first-line NSCLC patient data, in the second half of 2025. Instil Bio also plans to initiate its own U.S. clinical trial of SYN-2510/IMM2510 combined with chemotherapy for first-line NSCLC patients in the second half of 2025, pending regulatory approvals.

Instil Bio reported Q3 2024 financial results and corporate updates. The company licensed SYN-2510, a PD-L1xVEGF bispecific antibody, for global ex-China development. Cash position was $122.9M as of September 30, 2024, expected to fund operations beyond 2026. Q3 net loss per share was $3.54. Clinical updates include anticipated data from ImmuneOnco for SYN-2510 in 1H 2025, planned Phase 1b/2 studies in NSCLC and TNBC, and targeted U.S. clinical study initiation in 2H 2025.